Airway gene expression is dynamic with corticosteroid treatment and reflects disease activity

ABSTRACT: Introduction: In the recently completed Dutch GLUCOLD study, treatment of COPD patients with fluticasone ± salmeterol reduced the rate of decline in FEV1. These results indicate that ICS can have therapeutic efficacy in COPD. Aim: To explore the molecular mechanisms by which ICS exert their effects, we performed genome-wide gene expression profiling on bronchial biopsies from COPD patients who participated in the GLUCOLD study. Methods: An Affymetrix Human Gene Array ST version 1.0 was performed in a total of 221 bronchial biopsies that were available from 90 COPD patients at baseline and after 6 and 30 months of therapy. Linear mixed effects modeling was used to analyze treatment-specific changes in gene expression. A validation set was included and pathway analysis was performed with Gen

ORGANISM(S): Homo sapiens

SUBMITTER: Maarten van den Berge 

PROVIDER: E-GEOD-36221 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress